""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index

 

Mary E. Abood, PhD

Mary E. Abood, PhD

 

Professor, Anatomy and Cell Biology

Professor, Center for Substance Abuse Research

Telephone:  215-707-2638

Email:  mabood@temple.edu

 

Department of Anatomy and Cell Biology

Center for Substance Abuse Research

 

Educational Background:

 

BA Chemistry, Carleton College, Northfield, MN

 

PhD, Pharmacology, University of California San Francisco, San Francisco, CA

    

Postdoctoral Fellowship, Department of Psychiatry, Stanford University, Stanford, CA

    

Return to top

 

 

professional affiliations:

 

  • American Society for Pharmacology and Experimental Therapeutics
  • College on Problems of Drug Dependence
  • International Cannabinoid Research Society
  • Society for Neuroscience

Return to top

 

 

Research Interests:

 

Dr. Abood's laboratory is investigating recently discovered endogenous compounds called the endocannabinoids and their cellular receptors. The endocannabinoid system is thought to play a role in addiction, pain control, motor control, learning, and memory as well as in regulating immune function and bone growth. Her lab has cloned the CB1 and CB2 receptors and identified some of the structural and concomitant functional features of these receptor molecules. These studies are designed to elucidate the molecular mechanisms of CB receptor action. The endocannabinoid system is also involved in neuronal cell fate and neurodegeneration; her laboratory has published several papers on the role of cannabinoids in excitotoxicity and in the neurodegenerative disease ALS. More recently, she has focused on identifying novel cannabinoid receptor subtypes. These efforts have led to the identification of GPR55 as a putative cannabinoid receptor and GPR35 as a novel target for inflammation.

 

Return to top

 

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

25033246. Brailoiu GC, Deliu E, Marcu J, Hoffman NE, Console-Bram LM, Zhao P, Muniswamy M, Abood ME, Brailoiu E, Differential Activation of Intracellular vs Plasmalemmal CB2 Cannabinoid Receptors. Biochemistry :()2014 Jul 17

24762058. Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME, Activation of GPR18 by Cannabinoid compounds: A tale of biased agonism. Br J Pharmacol :()2014 Apr 25

24366865. Shore DM, Baillie GL, Hurst DH, Navas F 3rd, Seltzman HH, Marcu JP, Abood ME, Ross RA, Reggio PH, Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem 289:9(5828-45)2014 Feb 28

24347166. Zhao P, Lane TR, Gao HG, Hurst DP, Kotsikorou E, Le L, Brailoiu E, Reggio PH, Abood ME, Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem 289:6(3625-38)2014 Feb 7

24274581. Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, Reggio PH, Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52:52(9456-69)2013 Dec 31

24120859. Palma J, Abood ME, Barbe MF, Benamar K, Functional interaction between HIV-gp120 and opioid system in the preoptic anterior hypothalamus. Drug Alcohol Depend 134:(383-6)2014 Jan 1

23814062. Yu J, Deliu E, Zhang XQ, Hoffman NE, Carter RL, Grisanti LA, Brailoiu GC, Madesh M, Cheung JY, Force T, Abood ME, Koch WJ, Tilley DG, Brailoiu E, Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem 288:31(22481-92)2013 Aug 2

23426954. Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, Abood ME, Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2. J Pharmacol Exp Ther 345:2(189-97)2013 May

23160940. Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, Ross RA, CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:2(322-38)2013 Feb

22834041. Heynen-Genel S, Dahl R, Shi S, Sauer M, Hariharan S, Sergienko E, Dad S, Chung TDY, Stonich D, Su Y, Zhao P, Caron MG, Abood ME, Barak LS, Selective GPR35 Antagonists - Probe 3 :()2010

22820167. Zhao P, Abood ME, GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci 92:8-9(453-7)2013 Mar 19

22454039. Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME, The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol 7:4(856-65)2012 Dec

22421596. Console-Bram L, Marcu J, Abood ME, Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry 38:1(4-15)2012 Jul 2

22091481. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Caron MG, Barak LS, Abood ME, Screening for Selective Ligands for GPR55 - Antagonists :()2010

22091480. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Bravo Y, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Barak LS, Abood ME, Screening for Selective Ligands for GPR55 - Agonists :()2010

21719698. Brailoiu GC, Oprea TI, Zhao P, Abood ME, Brailoiu E, Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem 286:33(29166-74)2011 Aug 19

21534610. Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH, Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50:25(5633-47)2011 Jun 28

21433393. Heynen-Genel S, Dahl R, Shi S, Sauer M, Hariharan S, Sergienko E, Dad S, Chung TDY, Stonich D, Su Y, Caron M, Zhao P, Abood ME, Barak LS, Selective GPR35 Antagonists - Probes 1 & 2 :()2010

21397004. Persidsky Y, Ho W, Ramirez SH, Potula R, Abood ME, Unterwald E, Tuma R, HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. Brain Behav Immun 25 Suppl 1:(S61-70)2011 Jun

21185816. Kotsikorou E, Lynch DL, Abood ME, Reggio PH, Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem Phys Lipids 164:2(131-43)2011 Feb

21079038. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA, International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:4(588-631)2010 Dec

20826425. Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TD, Bai Y, Chen W, Caron MG, Barak LS, Abood ME, Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and -arrestin2 with antinociceptive activity. Mol Pharmacol 78:4(560-8)2010 Oct

20590559. Scotter EL, Abood ME, Glass M, The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:3(480-98)2010 Jun

20439484. Carter GT, Abood ME, Aggarwal SK, Weiss MD, Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 27:5(347-56)2010 Aug

20298715. Sharir H, Abood ME, Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126:3(301-13)2010 Jun

19723626. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME, Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284:43(29817-27)2009 Oct 23

19654014. Zhao P, Leonoudakis D, Abood ME, Beattie EC, Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology 58:2(551-8)2010 Feb

19332079. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF, CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res 78:1(86-94)2009 Jun

18752948. Nomura DK, Hudak CS, Ward AM, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman AH, Casida JE, Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett 18:22(5875-8)2008 Nov 15

18279310. Zhao P, Ignacio S, Beattie EC, Abood ME, Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci 27:3(572-9)2008 Feb

18174385. Kapur A, Samaniego P, Thakur GA, Makriyannis A, Abood ME, Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther 325:1(341-8)2008 Apr

17644043. Gehani NC, Nalwalk JW, Razdan RK, Martin BR, Sun X, Wentland M, Abood ME, Hough LB, Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain 8:11(850-60)2007 Nov

17595161. Anavi-Goffer S, Fleischer D, Hurst DP, Lynch DL, Barnett-Norris J, Shi S, Lewis DL, Mukhopadhyay S, Howlett AC, Reggio PH, Abood ME, Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem 282:34(25100-13)2007 Aug 24

17384224. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, Abood ME, Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71:6(1512-24)2007 Jun

16806300. Hough LB, de Esch IJ, Janssen E, Phillips J, Svokos K, Kern B, Trachler J, Abood ME, Leurs R, Nalwalk JW, Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology 51:3(447-56)2006 Sep

16781706. Kim K, Moore DH, Makriyannis A, Abood ME, AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 542:1-3(100-5)2006 Aug 7

16596772. Abood ME, Molecular biology of cannabinoid receptors. Handb Exp Pharmacol :168(81-115)2005

16157695. Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, Abood ME, Reggio PH, Fournier DJ, Makriyannis A, (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol 68:6(1623-35)2005 Dec

16078104. McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, Aldape K, Yount G, Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74:1(31-40)2005 Aug

15326174. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME, Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem 279:46(48024-37)2004 Nov 12

15204022. Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME, Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 5:1(33-9)2004 Mar

14613317. McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL, Reggio PH, Abood ME, An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46:24(5139-52)2003 Nov 20

12110371. McAllister SD, Tao Q, Barnett-Norris J, Buehner K, Hurst DP, Guarnieri F, Reggio PH, Nowell Harmon KW, Cabral GA, Abood ME, A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol 63:12(2121-36)2002 Jun 15

11514075. Abood ME, Rizvi G, Sallapudi N, McAllister SD, Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:3(197-201)2001 Aug 31

11334443. Kinard TA, Goforth PB, Tao Q, Abood ME, Teague J, Satin LS, Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion. Diabetes 50:5(992-1003)2001 May

11159703. Griffin G, Williams S, Aung MM, Razdan RK, Martin BR, Abood ME, Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues. Br J Pharmacol 132:2(525-35)2001 Jan

11020293. Mahadevan A, Siegel C, Martin BR, Abood ME, Beletskaya I, Razdan RK, Novel cannabinol probes for CB1 and CB2 cannabinoid receptors. J Med Chem 43:20(3778-85)2000 Oct 5

10940540. Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR, Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 60:2(133-40)2000 Aug 1

10688601. Griffin G, Tao Q, Abood ME, Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292:3(886-94)2000 Mar

10658595. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR, 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:12(2905-14)1999 Dec

Return to top

 

 

TEACHING:

 

  • Virginia Commonwealth University, School of Medicine
  • Director, Core Pharmacology Course for graduate students, 1993-1998
  • Pharmacology Conference for Pharmacy students, 1991-1999
  • Temple University School of Medicine

    Cellular Pharmacology lecture on Tyrosine Kinases, 2008-present

    Dental Neuroanatomy lecture on Sensory Systems, 2009

    Pharmacology of Drugs of Abuse lecture on Cannabinoids, 2010

    Neuropharmacology lecture on Cannabinoid Receptors, 2009, 2011

    Development, Structure and Function of the Musculoskeletal System lecture on the Endocannabinoid System in Bone, 2010, 2011

    Seminars in Cell Biology, faculty moderator, 2009-present

 

Return to top

 

 

TRAINEES:

 

Postdoctoral Fellows and Other Scientists Supervised:

Colleen McLaughlin, Ph.D., 1992-95
(now McCue)
Law Enforcement Program
Manager, SPADAC
(Spatial intelligence and Predictive Analytics)

Graeme Griffin, Ph.D., 1997-99
Associate Director, Business Development
Astellas Pharma


Qing Tao, M.D., 1994-99
Research Associate
Virginia Commonwealth University

Sean McAllister, PhD, 1999-2004

Scientist, Cal Pacific Medical Center, San Francisco

 

Neetha Sallapudi,  MD, 1999-2000

in private practice

 

Sharon Anavi-Goffer, PhD, 2002-2003

Senior Lecturer, Ariel University of Samaria

                             

Chandrasekeran Raman, PhD, 2001-2004

Scientist, Xenoport

             

Ankur Kapur, PhD, 2005-2010

Investigator II, Novartis Institute for Biomedical Research

 

Pingwei Zhao, PhD, 2005-2010

Associate Scientist, Temple University

 

Haleli Sharir, PhD, 2008-present

 

Linda Console-Bram, PhD, 2010-present

 

Graduate Students Supervised (as Primary Advisor):

Sean McAllister, PhD 1999
Vincent Showalter, PhD 1996
Jahan Marcu, PhD Candidate, Temple University


Return to top